Literature DB >> 1157045

The therapeutic response of three human tumor lines maintained in immune-suppressed mice.

L Kopper, G G Steel.   

Abstract

Studies were made of the growth and therapeutic response of three lines of human tumor serially transplanted in immune-suppressed mice. They included a well-differentiated colonic carcinoma (HX 13), a poorly differentiated colonic carcinoma (HX 18), and undifferentiated small-cell carcinoma of the bronchus (HX 29). Their histological appearance and growth rates were stable, with volume-doubling times ranging from 6 to 12 days. Studies by the technique of labeled mitoses showed that the growth kinetics of the three tumor lines were very similar, with median intermitotic times in the range of 26 to 35 hr. An analysis of the incidence of single and double takes revealed evidence for variation in susceptibility among the recipient mice. One tumor (HX 18) was transplantable with single-cell suspensions but 10(5) cells were required for 50 percent takes. The response of the tumors to a range of chemotherapeutic agents was studied. There was evidence that drugs that are known to be effective in the treatment of patients did well, in particular 5-fluorouracil against the colonic tumors and cyclophosphamide against the bronchial carcinoma. Long-term regressions induced by cyclophosphamide in the bronchial carcinoma may reflect assistance from host defense mechanisms.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1157045

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Cell proliferation in human tumours growing in nude mice: renal cell carcinomas, larynx and hypopharynx carcinomas.

Authors:  B Maurer-Schultze; I D Bassukas; M Böswald; M Harasim
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.

Authors:  Noémi Nagy; Melinda Hajdu; Ágnes Márk; Péter Attila Király; Mónika Tóth; Titanilla Dankó; Mónika Csóka; Anna Sebestyén
Journal:  Tumour Biol       Date:  2016-07-29

Review 3.  Human tumor xenografts as model for drug testing.

Authors:  J Mattern; M Bak; E W Hahn; M Volm
Journal:  Cancer Metastasis Rev       Date:  1988-11       Impact factor: 9.264

Review 4.  Predictive testing in cancer chemotherapy. I. In vivo.

Authors:  P H Slee; A T Van Oosterom; E A De Bruijn
Journal:  Pharm Weekbl Sci       Date:  1985-06-21

5.  Successful in vitro growth of human head and neck cancer after transplantation in nude mice.

Authors:  E C Heinerman; B J Braakhuis; G H Boerrigter; G B Snow
Journal:  Arch Otorhinolaryngol       Date:  1985

6.  The comparative disposition of the pyrolloquinone GR63178A and its 9-hydroxy metabolite GR54374X in sensitive and resistant mouse colon adenocarcinoma.

Authors:  R C French; J Cummings; A MacLellan; J S MacPherson; A A Ritchie; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  The potential of the nude mouse xenograft model for the study of head and neck cancer.

Authors:  B J Braakhuis; G Sneeuwloper; G B Snow
Journal:  Arch Otorhinolaryngol       Date:  1984

8.  Antitumor action of N-(2-chloroethyl)-N-nitrosocarbamoyl derivatives of biologically active polypeptide hormone fragments.

Authors:  A Jeney; L Kopper; P Nagy; K Lapis; H Süli-Vargha; K Medzihradszky
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  CB 1954 revisited. I. Disposition kinetics and metabolism.

Authors:  P Workman; R A White; K Talbot
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  17beta-Oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response.

Authors:  E C Chinje; K J Williams; B A Telfer; P J Wood; A J van der Kogel; I J Stratford
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.